EG16987A - Process for preparing novel 1,4-dihydropyridine derivatives - Google Patents

Process for preparing novel 1,4-dihydropyridine derivatives

Info

Publication number
EG16987A
EG16987A EG163/83A EG16383A EG16987A EG 16987 A EG16987 A EG 16987A EG 163/83 A EG163/83 A EG 163/83A EG 16383 A EG16383 A EG 16383A EG 16987 A EG16987 A EG 16987A
Authority
EG
Egypt
Prior art keywords
alkyl
preparing novel
dihydropyridine derivatives
hydrogen
independently
Prior art date
Application number
EG163/83A
Other languages
English (en)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10528947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG16987(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of EG16987A publication Critical patent/EG16987A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Mechanical Pencils And Projecting And Retracting Systems Therefor, And Multi-System Writing Instruments (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)
  • Luminescent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EG163/83A 1982-03-11 1983-03-09 Process for preparing novel 1,4-dihydropyridine derivatives EG16987A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8207180 1982-03-11

Publications (1)

Publication Number Publication Date
EG16987A true EG16987A (en) 1991-03-30

Family

ID=10528947

Family Applications (1)

Application Number Title Priority Date Filing Date
EG163/83A EG16987A (en) 1982-03-11 1983-03-09 Process for preparing novel 1,4-dihydropyridine derivatives

Country Status (37)

Country Link
US (1) US4572909A (en:Method)
EP (1) EP0089167B1 (en:Method)
JP (1) JPS58167569A (en:Method)
KR (1) KR870000809B1 (en:Method)
AT (1) ATE22884T1 (en:Method)
AU (1) AU540769B2 (en:Method)
BA (2) BA97147B1 (en:Method)
BG (1) BG60658B2 (en:Method)
CA (1) CA1253865A (en:Method)
CS (3) CS240954B2 (en:Method)
DD (2) DD209622A5 (en:Method)
DE (2) DE19375111I2 (en:Method)
DK (1) DK161312C (en:Method)
EG (1) EG16987A (en:Method)
ES (2) ES8503654A1 (en:Method)
FI (1) FI81090C (en:Method)
GR (1) GR77429B (en:Method)
HK (1) HK16288A (en:Method)
HR (2) HRP930370B1 (en:Method)
HU (1) HU187868B (en:Method)
IE (2) IE54765B1 (en:Method)
IL (1) IL68091A (en:Method)
KE (1) KE3778A (en:Method)
LU (1) LU88332I2 (en:Method)
LV (2) LV5236A3 (en:Method)
MY (1) MY101985A (en:Method)
NL (1) NL930063I2 (en:Method)
NO (3) NO162818C (en:Method)
NZ (1) NZ203521A (en:Method)
PL (3) PL140278B1 (en:Method)
PT (1) PT76370B (en:Method)
SG (1) SG98687G (en:Method)
SI (2) SI8310586A8 (en:Method)
SU (2) SU1238730A3 (en:Method)
UA (2) UA7082A1 (en:Method)
YU (2) YU43541B (en:Method)
ZA (1) ZA831651B (en:Method)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4572908A (en) * 1982-12-21 1986-02-25 Pfizer Inc. Dihydropyridines
GB8306666D0 (en) * 1983-03-10 1983-04-13 Pfizer Ltd Therapeutic agents
EP0125803A3 (en) * 1983-04-27 1987-01-21 FISONS plc Pharmaceutically active dihydropyridines
EP0168841B1 (en) * 1983-12-19 1988-09-28 Pfizer Limited Dihydropyridine intermediate
JPS60156671A (ja) * 1984-01-25 1985-08-16 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン誘導体およびその製造法
GB8414518D0 (en) * 1984-06-07 1984-07-11 Pfizer Ltd Therapeutic agents
GR851819B (en:Method) * 1984-08-17 1985-11-26 Wyeth John & Brother Ltd
GB8421039D0 (en) * 1984-08-17 1984-09-19 Wyeth John & Brother Ltd Heterocyclic compounds
IL77843A (en) * 1985-02-11 1989-07-31 Syntex Inc Dihydropyridine derivatives,process and novel intermediates for their preparation and pharmaceutical compositions containing them
EP0200524A3 (en) * 1985-05-03 1987-06-16 Pfizer Limited Dihydropyridine calcium antagonists
DE3531498A1 (de) * 1985-09-04 1987-03-05 Bayer Ag Dihydropyridin-2-hydroxyamine, verfahren zur herstellung und ihre verwendung in arzneimitteln
EP0225175A3 (en) * 1985-11-28 1988-12-28 FISONS plc Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof
DE3544211A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Neue, fluorhaltige 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
IT1204460B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
FR2602231B1 (fr) * 1986-08-04 1988-10-28 Adir Nouveaux derives de la dihydro-1,4 pyridine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2649395B1 (fr) * 1989-07-04 1992-11-06 Adir Nouveau derive de la dihydro-1,4 pyridine denomme (-) Ÿi1Ÿ(((amino-2 ethoxy)-2 ethoxy) methylŸi1Ÿ) -2 (dichloro-2,3 phenyl)-4 ethoxycarbonyl-3 methoxycarbonyl-5 methyl-6 dihydro-1,4 pyridine, son procede de preparation et les compositions qui le contiennent
US4983740A (en) * 1986-08-04 1991-01-08 Adir Et Compagnie Process for 1,4-dihydropyridine compounds
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
IT1213555B (it) * 1986-12-11 1989-12-20 Boehringer Biochemia Srl 2 metiltiometildiidropiridine, un processo per laloro preparazione e composizioni farmaceutiche che le contengono.
JPS63196564A (ja) * 1987-02-10 1988-08-15 Agency Of Ind Science & Technol イミドオリゴマ−の製造方法
IT1215381B (it) * 1987-03-12 1990-02-08 Boehringer Biochemia Srl Farmaceutiche che le contengono. carbonil- e solfonil- derivati di 2-(aminoalchiltio)metil-1,4-diidropiridine, un metodo per la loro preparazione e composizioni
GB8709447D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Dihydropyridines
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
DE3906406C1 (en:Method) * 1989-03-01 1990-10-25 Goedecke Ag, 1000 Berlin, De
DE4128132A1 (de) * 1991-08-24 1993-02-25 Bayer Ag 3-(2-chlor-3-trifluormethylphenyl)-4-cyanopyrrol, dessen herstellung und verwendung und neue zwischenprodukte
US5234943A (en) * 1989-04-13 1993-08-10 Bayer Aktiengesellschaft Fungicidal 3-(2-chloro-3-trifluoromethylphenyl)-4-cyanopyrrole
FR2652083B1 (fr) * 1989-09-20 1992-01-24 Ador Cie Nouveau procede de separation d'isomeres optiques des derives de la dihydro-1,4 pyridine.
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
WO1993010779A1 (en) * 1991-11-26 1993-06-10 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP1614420A3 (en) * 1992-11-25 2006-04-19 Sepracor Inc. Treatment of hypertension, angina and other disorders using (-) amlodipine
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0804229B1 (en) 1995-03-16 2003-03-26 Pfizer Inc. Use of amlodipine, a salt thereof or felodipin in combination with an ace inhibitor in the manufacture of a medicament for the treatment of nonischemic congestive heart failure
NZ280378A (en) * 1995-11-01 1998-04-27 Apotex Inc 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid compounds, preparation, intermediate compounds
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ZA9810319B (en) * 1997-11-14 2000-05-11 Gea Farmaceutisk Fabrik As Process for the preparation of acetal derivatives of 1,4-dihydropyridines, novel acetal derivatives and the use of the acetal derivatives for the preparation of other 1,4-dihydropyridines.
ZA9810320B (en) * 1997-11-14 2000-05-11 Gea Farmaceutisk Fabrik As Process for the preparation of 1,4-dihydropyridines and novel compounds of use for such purpose.
ES2151850B1 (es) * 1998-10-26 2001-08-16 Esteve Quimica Sa Intermedio para la sintesis de amlodipino para su obtencion y utilizacion correspondiente.
RU2142942C1 (ru) * 1999-04-28 1999-12-20 Дж. Б.Кемикалс энд Фармасьютикалс Лтд. Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
AP2001002345A0 (en) 1999-05-27 2001-12-31 Pfizer Prod Inc Mutual prodrugs of amlodipine and atorvastatin.
UA72768C2 (en) * 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
RU2146672C1 (ru) * 1999-10-13 2000-03-20 Др.Редди'С Лабораторис Лтд. Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
CN1091441C (zh) * 1999-12-04 2002-09-25 昆明赛诺制药有限公司 甲磺酸氨氯地平及其制法和应用
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
IL152021A0 (en) * 2000-04-11 2003-04-10 Sankyo Co Pharmaceutical compositions containing pyridine derivatives
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
DE60112305T2 (de) * 2000-12-29 2006-05-24 Pfizer Ltd., Sandwich Verfahren zur herstellung amlodipinmaleat
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
CZ20031779A3 (cs) * 2000-12-29 2004-10-13 Bioorganicsáb@V Způsob přípravy amlodipinuŹ jeho derivátů a jejich prekurzorů
BR0116552A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão
EP1309556B1 (en) 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
EP1346214A2 (en) * 2000-12-29 2003-09-24 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
WO2002053540A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Aspartate derivative of amlodipine as calcium channel antagonist
EA008141B1 (ru) * 2000-12-29 2007-04-27 Пфайзер Лимитед Способ получения малеата амлодипина
KR100374767B1 (ko) * 2001-03-13 2003-03-03 한미약품공업 주식회사 개선된 암로디핀의 제조 방법
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US7153970B2 (en) 2001-07-06 2006-12-26 Lek Pharmaceuticals D.D. High purity amlodipine benzenesulfonate and a process for its preparation
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
GB0120808D0 (en) * 2001-08-28 2001-10-17 Pfizer Ltd Crystalline material
US20030180354A1 (en) * 2001-10-17 2003-09-25 Dr. Reddy's Laboratories Limited Amlodipine maleate formulations
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US6562983B1 (en) * 2002-03-18 2003-05-13 Council Of Scientific And Industrial Research Process for the preparation of alkyl 4[2-(phthalimido)ethoxy]-acetoacetate
WO2003089414A1 (en) * 2002-04-13 2003-10-30 Hanlim Pharmaceutical Co., Ltd. Amlodipine nicotinate and process for the preparation thereof
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
KR100496436B1 (ko) 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
DE60336485D1 (de) 2002-08-19 2011-05-05 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
KR100467669B1 (ko) 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
AU2003260984A1 (en) * 2002-09-11 2004-04-30 Hanlim Pharmaceutical Co., Ltd. S-(-)-amlodipine nicotinate and process for the preparation thereof
AU2003253460A1 (en) 2002-09-19 2004-04-08 Cj Corporation Crystalline organic acid salt of amlodipine
KR100596369B1 (ko) 2002-09-19 2006-07-03 씨제이 주식회사 결정형의 암로디핀 유기산염
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
BRPI0406987A (pt) * 2003-01-31 2006-01-10 Sankyo Co Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
CA2559670A1 (en) * 2003-04-14 2004-10-28 Gabor Pragai Stable amlodipine maleate formulations
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
DE112004000712T5 (de) * 2003-04-25 2006-10-19 Cipla Ltd. Verfahren zur Herstellung von Amlodipinmesilat-Monohydrat
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
AU2004247627A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7923467B2 (en) * 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
CH697952B1 (de) * 2003-07-25 2009-03-31 Siegfried Generics Int Ag Verfahren zur Reinigung der freien Amlodipinbase.
WO2005023769A1 (en) * 2003-09-04 2005-03-17 Cipla Limited Process for the preparation of amlodipine salts
CA2538188A1 (en) * 2003-09-10 2005-03-24 Synta Pharmaceuticals Corp. Dihydropyridine compounds for treating or preventing metabolic disorders
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005089353A2 (en) * 2004-03-16 2005-09-29 Sepracor Inc. (s)-amlodipine malate
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006003672A1 (en) * 2004-07-02 2006-01-12 Matrix Laboratories Ltd Process for the preparation of pure amlodipine
RU2007106714A (ru) * 2004-07-26 2008-09-10 Байер Шеринг Фарма Аг (De) Лечение легочной гипертензии путем ингаляции илопростата с препаратом микрочастиц
PL1814527T5 (pl) * 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
BRPI0612674B8 (pt) * 2005-06-27 2021-05-25 Daiichi Sankyo Co Ltd preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
CA2613875C (en) * 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
ES2265781B1 (es) * 2005-08-04 2007-12-01 Ercros Industrial, S.A. Procedimiento para la obtencion de besilato de amlodipina.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
ATE551059T1 (de) 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
US20070260065A1 (en) * 2006-05-03 2007-11-08 Vijayabhaskar Bolugoddu Process for preparing amlodipine
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
KR100830003B1 (ko) 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
CN101230035B (zh) * 2007-03-23 2010-11-03 浙江尖峰药业有限公司 门冬氨酸氨氯地平系列盐及其制备方法和其组合物、制剂以及片剂
EP1975167A1 (en) * 2007-03-30 2008-10-01 Esteve Quimica, S.A. Acetone solvate of phthaloyl amlodipine
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20090062352A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched amlodipine
US8748648B2 (en) * 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
WO2009084003A1 (en) * 2007-12-31 2009-07-09 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
WO2009113420A1 (ja) 2008-03-13 2009-09-17 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
CN101560181B (zh) * 2008-04-16 2013-02-27 北京万全阳光医学技术有限公司 一种氨氯地平游离碱的制备方法
CN101367759B (zh) * 2008-10-06 2011-03-16 北京赛科药业有限责任公司 一种高纯度苯磺酸氨氯地平的合成方法
JP2010100562A (ja) * 2008-10-23 2010-05-06 Daito Kk アムロジピン製造中間体の精製方法
KR20140069381A (ko) 2009-06-02 2014-06-10 다우 글로벌 테크놀로지스 엘엘씨 서방출 투여형
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2575808A1 (en) 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
WO2011152803A1 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
TR201100152A2 (tr) 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Amlodipin içeren efervesan bileşimler.
CN102070516A (zh) * 2011-02-22 2011-05-25 广东东阳光药业有限公司 一种制备氨氯地平的方法
WO2012123966A1 (en) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Process for the preparation of 4 -substituted -1, 4-dihydropyridines
UA110244C2 (en) 2011-04-12 2015-12-10 Boryung Pharm Antihypertensive pharmaceutical composition
RU2570752C2 (ru) 2011-08-26 2015-12-10 Вокхардт Лимитед Способы лечения сердечно-сосудистых нарушений
CN102382041B (zh) * 2011-12-02 2016-01-20 东北制药集团股份有限公司 一种马来酸氨氯地平的制备方法
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
CN103044314A (zh) * 2013-01-06 2013-04-17 先声药业有限公司 马来酸氨氯地平的制备方法
JP5952748B2 (ja) * 2013-01-25 2016-07-13 東和薬品株式会社 フタロイルアムロジピンの新規結晶形態およびそれを用いる高純度なアムロジピンベシル酸塩の製造方法
US20150374713A1 (en) 2013-02-08 2015-12-31 Wockhardt Limited Stable pharmeceutical composition of amlodipine and benazepril or salts thereof
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
ES2847904T3 (es) 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CN104262237A (zh) * 2014-09-28 2015-01-07 常州瑞明药业有限公司 氨氯地平自由碱的合成方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CZ2015687A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
US20180303811A1 (en) 2015-10-23 2018-10-25 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CA3015964C (en) 2016-03-24 2021-08-03 Daiichi Sankyo Company, Limited Medicine for treating renal disease
EP3463309B1 (en) 2016-05-30 2020-06-17 Boehringer Ingelheim International GmbH Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
WO2018067959A1 (en) 2016-10-07 2018-04-12 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3773574A4 (en) 2018-04-11 2022-03-02 Silvergate Pharmaceuticals, Inc. AMLODIPINE FORMULATIONS
AU2019285170A1 (en) 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
CN120154071A (zh) 2019-05-21 2025-06-17 雀巢产品有限公司 膳食丁酸酯
GB2595203A (en) 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
GB2636158A (en) 2023-12-01 2025-06-11 Novumgen Ltd An orally disintegrating tablet containing amlodipine or pharmaceutically acceptable salts thereof and the process of preparing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
SE7910521L (sv) * 1979-12-20 1981-06-21 Haessle Ab Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DE3739854A1 (de) * 1987-11-25 1989-06-08 Philips Patentverwaltung Verfahren zur herstellung von titandioxid-pulver

Also Published As

Publication number Publication date
CS149983A2 (en) 1985-06-13
HK16288A (en) 1988-03-11
NO162818C (no) 1990-02-21
KR870000809B1 (ko) 1987-04-20
CS159284A2 (en) 1985-06-13
EP0089167A3 (en) 1984-07-11
PL250767A1 (en) 1985-12-17
UA7083A1 (uk) 1995-06-30
IE54765B1 (en) 1990-01-31
FI81090B (fi) 1990-05-31
BG60658B2 (en) 1995-11-30
PL140278B1 (en) 1987-04-30
SU1227110A3 (ru) 1986-04-23
FI81090C (fi) 1990-09-10
SI8310586A8 (sl) 1996-02-29
LV5235A3 (lv) 1993-10-10
SG98687G (en) 1988-09-23
GR77429B (en:Method) 1984-09-14
NO170275B (no) 1992-06-22
LU88332I2 (fr) 1994-05-04
LV5236A3 (lv) 1993-10-10
HU187868B (en) 1986-02-28
DK81383A (da) 1983-09-12
YU58683A (en) 1986-06-30
IE863092L (en) 1983-09-11
PT76370A (en) 1983-04-01
NO864435L (no) 1983-09-12
BA98207B1 (bs) 1999-08-02
ES526459A0 (es) 1985-05-16
DD218887A5 (de) 1985-02-20
AU1235183A (en) 1983-09-22
MY101985A (en) 1992-02-29
ZA831651B (en) 1983-12-28
NO1994020I1 (no) 1994-11-02
NO864435D0 (no) 1986-11-06
SU1238730A3 (ru) 1986-06-15
FI830789L (fi) 1983-09-12
IE54667B1 (en) 1990-01-03
CA1253865A (en) 1989-05-09
PL240854A1 (en) 1985-04-09
PL141830B1 (en) 1987-08-31
DE19375111I2 (de) 2001-06-13
FI830789A0 (fi) 1983-03-09
KE3778A (en) 1987-11-27
ES8505201A1 (es) 1985-05-16
DD209622A5 (de) 1984-05-16
US4572909A (en) 1986-02-25
ES520389A0 (es) 1985-03-16
KR840004073A (ko) 1984-10-06
EP0089167B1 (en) 1986-10-15
HRP930370B1 (en) 1996-02-29
IL68091A (en) 1986-11-30
BA97147B1 (bs) 1998-12-28
NO162818B (no) 1989-11-13
DK81383D0 (da) 1983-02-23
YU141985A (en) 1986-06-30
DK161312B (da) 1991-06-24
NZ203521A (en) 1985-09-13
JPS58167569A (ja) 1983-10-03
UA7082A1 (uk) 1995-06-30
YU43541B (en) 1989-08-31
AU540769B2 (en) 1984-12-06
ES8503654A1 (es) 1985-03-16
NO830847L (no) 1983-09-12
CS240954B2 (en) 1986-03-13
NL930063I1 (nl) 1993-09-01
JPS626703B2 (en:Method) 1987-02-13
EP0089167A2 (en) 1983-09-21
ATE22884T1 (de) 1986-11-15
YU43417B (en) 1989-06-30
SI8511419A8 (sl) 1996-10-31
DK161312C (da) 1991-12-09
DE3366920D1 (en) 1986-11-20
NO170275C (no) 1992-09-30
NL930063I2 (nl) 1993-10-01
CS418891A3 (en) 1992-09-16
PT76370B (en) 1986-03-27
IE830520L (en) 1983-09-11
PL140575B1 (en) 1987-05-30
IL68091A0 (en) 1983-06-15
HRP930369B1 (en) 1996-02-29
CS240998B2 (en) 1986-03-13

Similar Documents

Publication Publication Date Title
EG16987A (en) Process for preparing novel 1,4-dihydropyridine derivatives
PL243130A1 (en) Process for preparing novel derivatives of 1,4-dihydropyridine